.jpg)
.jpg)
.jpg)
Amid industry's onshoring push, Regeneron taps Fujifilm Diosynth for $3B, 10-year commercial manufacturing team-up
Under a new 10-year agreement, Regeneron will pay CDMO powerhouse Fujifilm Diosynth Biotechnologies more than $3 billion to help manufacture bulk drug product for its commercial biologics in the United States. The move comes as many drugmakers operating in the U.S. attempt to bolster domestic production ahead of potential pharmaceutical import tariffs.
Under a new 10-year agreement, Regeneron will pay CDMO powerhouse Fujifilm Diosynth Biotechnologies more than $3 billion to help manufacture bulk drug product for its commercial biologics in the United States. The move comes as many drugmakers operating in the U.S. attempt to bolster domestic production ahead of potential pharmaceutical import tariffs.
